Goodwin Advises CMR Surgical on $400 Million Strategic Investment and Alliance With Stryker

The Life Sciences and Technology teams advised CMR Surgical, a global medical robotics company, on its strategic alliance with Stryker (NYSE: SYK), a global leader in medical technologies, to accelerate growth of CMR Surgical’s Versius Surgical Robotic portfolio. Under the terms of the agreement, Stryker will make an approximately $400 million (£300 million) preferred equity investment in CMR Surgical and receive an exclusive option to acquire 100% of CMR Surgical’s outstanding equity in the future. The alliance also includes an exclusive US commercial agency agreement under which Stryker will serve as the exclusive US sales agent for the Versius portfolio. The investment, which is subject to regulatory approvals and customary closing conditions, will support continued innovation and global commercialization of the Versius portfolio.

CMR Surgical is a global medical devices company dedicated to transforming surgery with Versius Plus, a next-generation surgical robot. Headquartered in Cambridge, United Kingdom, CMR is committed to working with surgeons, surgical teams, and hospital partners to provide an optimal tool to make robotic minimal access surgery universally accessible and affordable. With Versius Plus, CMR Surgical is on a mission to redefine the surgical robotics market with practical, innovative technology and data that can improve surgical care. Founded in 2014, CMR Surgical is a private limited company backed by an international shareholder base.

The Goodwin team was led by Liz Rhodes, Rob Dzialo, Steve Wheeler, Lucy Thomas and Bethany Withers.

For more information, please read the press release.